Cargando…

A case of durvalumab-induced lichenoid eruption evolving to bullous eruption after phototherapy: A case report

Immune checkpoint inhibitor therapy nowadays became a treatment for a wide range of cancers, and may be responsible for various dermatologic adverse effects, including bullous eruptions. In our report, we present a case of late-onset immunotherapy-induced eruption in a 62-year-old woman treated with...

Descripción completa

Detalles Bibliográficos
Autores principales: Manko, Svitlana, Côté, Benoît, Provost, Nathalie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7940716/
https://www.ncbi.nlm.nih.gov/pubmed/33747513
http://dx.doi.org/10.1177/2050313X21993279
_version_ 1783661999885910016
author Manko, Svitlana
Côté, Benoît
Provost, Nathalie
author_facet Manko, Svitlana
Côté, Benoît
Provost, Nathalie
author_sort Manko, Svitlana
collection PubMed
description Immune checkpoint inhibitor therapy nowadays became a treatment for a wide range of cancers, and may be responsible for various dermatologic adverse effects, including bullous eruptions. In our report, we present a case of late-onset immunotherapy-induced eruption in a 62-year-old woman treated with anti-programmed cell death-L1 agent durvalumab for metastatic squamous cell carcinoma. Diagnosed as lichenoid dermatitis upon initial presentation, this eruption evolved into necrotic bullous dermatitis after several weeks of phototherapy, with histology and direct immunofluorescence study favoring lichen planus pemphigoides. Thus, this case may be regarded as durvalumab-induced lichenoid dermatitis with phototherapy-triggered progression to necrotic lichen planus pemphigoides-like eruption. The patient’s eruption responded to oral prednisone and immunotherapy interruption. Interestingly, durvalumab reintroduction in this patient led to recurrent lichenoid dermatitis without bullous component. This case of immunotherapy skin toxicity is rather distinctive by its clinical and histopathologic features, with phototherapy as an additional triggering factor.
format Online
Article
Text
id pubmed-7940716
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-79407162021-03-18 A case of durvalumab-induced lichenoid eruption evolving to bullous eruption after phototherapy: A case report Manko, Svitlana Côté, Benoît Provost, Nathalie SAGE Open Med Case Rep JCMS Case Report Immune checkpoint inhibitor therapy nowadays became a treatment for a wide range of cancers, and may be responsible for various dermatologic adverse effects, including bullous eruptions. In our report, we present a case of late-onset immunotherapy-induced eruption in a 62-year-old woman treated with anti-programmed cell death-L1 agent durvalumab for metastatic squamous cell carcinoma. Diagnosed as lichenoid dermatitis upon initial presentation, this eruption evolved into necrotic bullous dermatitis after several weeks of phototherapy, with histology and direct immunofluorescence study favoring lichen planus pemphigoides. Thus, this case may be regarded as durvalumab-induced lichenoid dermatitis with phototherapy-triggered progression to necrotic lichen planus pemphigoides-like eruption. The patient’s eruption responded to oral prednisone and immunotherapy interruption. Interestingly, durvalumab reintroduction in this patient led to recurrent lichenoid dermatitis without bullous component. This case of immunotherapy skin toxicity is rather distinctive by its clinical and histopathologic features, with phototherapy as an additional triggering factor. SAGE Publications 2021-03-03 /pmc/articles/PMC7940716/ /pubmed/33747513 http://dx.doi.org/10.1177/2050313X21993279 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle JCMS Case Report
Manko, Svitlana
Côté, Benoît
Provost, Nathalie
A case of durvalumab-induced lichenoid eruption evolving to bullous eruption after phototherapy: A case report
title A case of durvalumab-induced lichenoid eruption evolving to bullous eruption after phototherapy: A case report
title_full A case of durvalumab-induced lichenoid eruption evolving to bullous eruption after phototherapy: A case report
title_fullStr A case of durvalumab-induced lichenoid eruption evolving to bullous eruption after phototherapy: A case report
title_full_unstemmed A case of durvalumab-induced lichenoid eruption evolving to bullous eruption after phototherapy: A case report
title_short A case of durvalumab-induced lichenoid eruption evolving to bullous eruption after phototherapy: A case report
title_sort case of durvalumab-induced lichenoid eruption evolving to bullous eruption after phototherapy: a case report
topic JCMS Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7940716/
https://www.ncbi.nlm.nih.gov/pubmed/33747513
http://dx.doi.org/10.1177/2050313X21993279
work_keys_str_mv AT mankosvitlana acaseofdurvalumabinducedlichenoideruptionevolvingtobullouseruptionafterphototherapyacasereport
AT cotebenoit acaseofdurvalumabinducedlichenoideruptionevolvingtobullouseruptionafterphototherapyacasereport
AT provostnathalie acaseofdurvalumabinducedlichenoideruptionevolvingtobullouseruptionafterphototherapyacasereport
AT mankosvitlana caseofdurvalumabinducedlichenoideruptionevolvingtobullouseruptionafterphototherapyacasereport
AT cotebenoit caseofdurvalumabinducedlichenoideruptionevolvingtobullouseruptionafterphototherapyacasereport
AT provostnathalie caseofdurvalumabinducedlichenoideruptionevolvingtobullouseruptionafterphototherapyacasereport